Amy Sehnert

About

Amy Sehnert is the Vice President and Head of Cardiomyopathy and Heart Failure Clinical Development at Bristol-Myers Squibb Co in the United States. Her research areas focus on hypertrophic cardiomyopathy, particularly the pharmacokinetics and clinical efficacy of mavacamten, as well as the development of patient-reported outcome instruments. Recent publications include investigations on the response to mavacamten in patients with obstructive hypertrophic cardiomyopathy and analyses of its long-term safety and efficacy.